Business Description
Evogene Ltd
SIC : 8731
ISIN : IL0011050551
Total Employee Number:
52Description
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.43 | |||||
Equity-to-Asset | -0.25 | |||||
Debt-to-Equity | -0.64 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -31.88 | |||||
Beneish M-Score | -0.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.5 | |||||
3-Year EBITDA Growth Rate | 38.1 | |||||
3-Year EPS without NRI Growth Rate | 31.9 | |||||
3-Year FCF Growth Rate | 33.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.22 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 31.51 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.74 | |||||
9-Day RSI | 42.45 | |||||
14-Day RSI | 43.63 | |||||
3-1 Month Momentum % | 14.65 | |||||
6-1 Month Momentum % | -24.33 | |||||
12-1 Month Momentum % | -52.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.57 | |||||
Quick Ratio | 3.54 | |||||
Cash Ratio | 3.06 | |||||
Days Inventory | 119.43 | |||||
Days Sales Outstanding | 138.3 | |||||
Days Payable | 65.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.3 | |||||
Shareholder Yield % | 119.37 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -112.49 | |||||
Operating Margin % | -1044.27 | |||||
Net Margin % | -694.17 | |||||
EBITDA Margin % | -883.47 | |||||
FCF Margin % | -837.98 | |||||
OCF Margin % | -836.6 | |||||
ROA % | -40.71 | |||||
ROIC % | -159.57 | |||||
3-Year ROIIC % | -95.96 | |||||
ROC (Joel Greenblatt) % | -236.56 | |||||
ROCE % | -77.45 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.76 | |||||
EV-to-EBIT | -0.78 | |||||
EV-to-EBITDA | -0.84 | |||||
EV-to-Revenue | 7.48 | |||||
EV-to-Forward-Revenue | 0.27 | |||||
EV-to-FCF | -0.89 | |||||
Price-to-GF-Value | 1.55 | |||||
Price-to-Median-PS-Value | 0.13 | |||||
Earnings Yield (Greenblatt) % | -128.03 | |||||
FCF Yield % | -137.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evogene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₪) | 4.139 | ||
| EPS (TTM) (₪) | -2.795 | ||
| Beta | 1.2312 | ||
| 3-Year Sharpe Ratio | -1.52 | ||
| 3-Year Sortino Ratio | -1.61 | ||
| Volatility % | 35.51 | ||
| 14-Day RSI | 43.63 | ||
| 14-Day ATR (₪) | 0.116786 | ||
| 20-Day SMA (₪) | 1.6194 | ||
| 12-1 Month Momentum % | -52.39 | ||
| 52-Week Range (₪) | 1.16 - 4.787 | ||
| Shares Outstanding (Mil) | 15.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evogene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evogene Ltd Stock Events
| Event | Date | Price (₪) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-05 | In 169 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-20 | In 64 days | ||
| Third quarter earnings results for 2026 | 2026-11-20 | In 64 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-18 09:00 | 1.79 (-6.28%) | ||
| Second quarter earnings results for 2026 | 2026-08-18 | 1.79 (-6.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-20 09:00 | 2.05 (+0.54%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 2.05 (+0.54%) | ||
| Annual report for 2025 | 2026-03-27 | 2.61 (-2.57%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 | 2.59 (-0.84%) |
Show
Entries
Evogene Ltd Frequently Asked Questions
What is Evogene Ltd(XTAE:EVGN)'s stock price today?
The current price of XTAE:EVGN is ₪1.53. The 52 week high of XTAE:EVGN is ₪4.79 and 52 week low is ₪1.16.
When is next earnings date of Evogene Ltd(XTAE:EVGN)?
The next earnings date of Evogene Ltd(XTAE:EVGN) is 2026-11-20 Est..
Does Evogene Ltd(XTAE:EVGN) pay dividends? If so, how much?
Evogene Ltd(XTAE:EVGN) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers